Komori
PRISM BioLab (206A) · RiskFirst stated

Legal and regulatory risks, including pharmaceutical regulations and product liability

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Uncertainty over regulatory compliance, approvals and launch delays for pharmaceuticals and regenerative medicine productsA theme 37 companies write about · 40 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 3 of 16 companies on the "Worse" side.

4 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「The pharmaceutical business is subject to various laws and regulations, including pharmaceutical regulations and product liability laws, and the enactment or revision of laws and regulations may have a material effect on business performance.」

    Risks related to compliance with and changes to laws and regulations, including the Pharmaceutical Affairs Law, regulatory approvals and product liability, were listed as a separate item.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PRISM BioLab yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Legal and regulatory risks, including pharmaceutical regulations and product liability | PRISM BioLab Co.,LTD (206A) | Komori